Arena Pharmaceuticals Inc (ARNA.OQ)
18 Jun 2018
Tue, May 8 2018
* EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018
BRIEF-Arena Pharmaceuticals To Release Q1 Financial Results And Provide Corporate Update On Tuesday, May 8
* ARENA PHARMACEUTICALS TO RELEASE FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON TUESDAY, MAY 8 Source text for Eikon: Further company coverage:
* ARENA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
BRIEF-Arena Pharmaceuticals To Offer 7.5 Mln Shares Of Its Common Stock In An Underwritten Public Offering
* ARENA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.
March 19 Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.
* ARENA PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS
- ASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The Fed
- MannKind Completes Phase 1 Clinical Trial On Treprostinil Product
- Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher
- Arena Pharmaceuticals (ARNA) Presents At 2018 UBS Global Healthcare Conference - Slideshow
- Arena Pharmaceuticals' (ARNA) CEO Presents at UBS Global Healthcare Brokers Conference (Transcript)
- Is A New MannKind Possible?